Back to top
more

Bausch Health (BHC)

(Delayed Data from NYSE)

$5.63 USD

5.63
3,565,166

-0.47 (-7.70%)

Updated Aug 2, 2024 04:00 PM ET

After-Market: $5.62 -0.01 (-0.18%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (71 out of 251)

Industry: Medical - Generic Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Bausch Health (BHC) Q2 Earnings In Line, Xifaxan Boosts Sales

by Zacks Equity Research

Bausch Health's (BHC) second-quarter adjusted earnings meet estimates while sales top the same, fueled by growth in Xifaxan sales.

Bausch (BHC) Reports Q2 Earnings: What Key Metrics Have to Say

by Zacks Equity Research

Although the revenue and EPS for Bausch (BHC) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Bausch Health (BHC) Beats Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Bausch (BHC) delivered earnings and revenue surprises of 10.11% and 2.97%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Bausch Health (BHC) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Bausch (BHC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Bausch (BHC) Q1 Earnings and Revenues Miss, Shares Fall

by Zacks Equity Research

Bausch's (BHC) first-quarter earnings and sales miss their respective estimates. Its shares fall in response to the results.

Bausch Health (BHC) Q1 Earnings and Revenues Miss Estimates

by Zacks Equity Research

Bausch (BHC) delivered earnings and revenue surprises of -21.33% and 1.39%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

All You Need to Know About Bausch (BHC) Rating Upgrade to Buy

by Zacks Equity Research

Bausch (BHC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Will Bausch (BHC) Beat Estimates Again in Its Next Earnings Report?

by Zacks Equity Research

Bausch (BHC) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Bausch (BHC) Starts Litigation Against Amneal for Xifaxan

by Zacks Equity Research

Bausch (BHC) initiates litigation against Amneal Pharmaceuticals and its subsidiaries over a generic version of its lead drug Xifaxan.

Here's Why Bausch Health (BHC) is a Strong Momentum Stock

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Bausch (BHC) Soars 6.4%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Bausch (BHC) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Why Bausch Health (BHC) is a Top Momentum Stock for the Long-Term

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Bausch (BHC) Q4 Earnings and Revenues Top Estimates

by Zacks Equity Research

Bausch (BHC) fourth-quarter earnings and sales beat their respective estimates. The guidance for 2024 looks encouraging.

Bausch (BHC) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates

by Zacks Equity Research

Although the revenue and EPS for Bausch (BHC) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Bausch Health (BHC) Surpasses Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Bausch (BHC) delivered earnings and revenue surprises of 13.86% and 7.15%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Will Bausch (BHC) Beat Estimates Again in Its Next Earnings Report?

by Zacks Equity Research

Bausch (BHC) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Ekta Bagri headshot

Biotech/Drug Stocks Q4 Earnings Due Feb 22: MRNA, BHC, NTLA, BMRN & More

by Ekta Bagri

Let us take a look at what's in store for biotech/drug stocks MRNA, BHC, NTLA, BMRN and ITCI, which are scheduled to report on Feb 22.

Analysts Estimate Supernus Pharmaceuticals (SUPN) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Supernus (SUPN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Insights Into Bausch (BHC) Q4: Wall Street Projections for Key Metrics

by Zacks Equity Research

Evaluate the expected performance of Bausch (BHC) for the quarter ended December 2023, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Analysts Estimate Bausch Health (BHC) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Bausch (BHC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Bausch (BHC) Upgraded to Strong Buy: What Does It Mean for the Stock?

by Zacks Equity Research

Bausch (BHC) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Best Value Stocks to Buy for February 7th

by Zacks Equity Research

MITSY, JSAIY and BHC made it to the Zacks Rank #1 (Strong Buy) value stocks list on February 7, 2023.

UnitedHealth Group's (UNH) Brazil Unit Draws Buyout Interests

by Zacks Equity Research

UnitedHealth Group (UNH) expects to divest its troubled Brazil business, enhancing its overall results.

Bausch Health (BHC) Ulcerative Colitis Drug Meets Primary Goal

by Zacks Equity Research

Bausch's (BHC) amiselimod achieves the primary and key secondary endpoints, including clinical and endoscopic measures, in the double-blind period of a phase II study.